The high HIV virulence route is through mucosal tissue; therefore, the initial mucosal antibody production is the substantial defense against HIV pathogens [[75], [76], [77]].
76. Duchemin M., Tudor D., Cottignies-Calamarte A., Bomsel M. Antibody-dependent cellular phagocytosis of HIV-1-infected cells is efficiently triggered by IgA targeting HIV-1 envelope subunit gp41. Front. Immunol. 2020;11 [PMC free article] [PubMed] [Google Scholar]
77. Bomsel M., Tudor D., Drillet A.-S., Alfsen A., Ganor Y., Roger M.-G., Mouz N., Amacker M., Chalifour A., Diomede L., Devillier G., Cong Z., Wei Q., Gao H., Qin C., Yang G.-B., Zurbriggen R., Lopalco L., Fleury S. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011;34(2):269–280. [PubMed] [Google Scholar]
Vaccination with the stable forms of the virosomal HIV-1 candidate vaccine should elicit relevant protective antibodies, even if the product has been stored accidentally for a few days or weeks at 40 °C or frozen during shipment [57,81,82].
82. Kozlowski P.A., Aldovini A. Mucosal vaccine approaches for prevention of HIV and SIV transmission. Curr. Immunol. Rev. 2019;15(1):102–122. [PMC free article] [PubMed] [Google Scholar]
Virosome therapeutic agents were developed more significantly in multimodal vehicles against advanced-stage cancer. Virosome is the desired carrier for immunogenic substances and chemotropic agent delivery in oncologic fields. Oncolytic viruses comprise natural and recombinant mutants that replicate in tumor cells and reinforce anti-tumor functions [85]. Virosome could make delivery tumor antigens, including Tumor-Specific Antigens (TSA) and Tumor-Associated Antigens (TAA). Virosome compression to the viral vector has much safety and is persuaded to be used. The HVJ; Sendai virus can serve as multimodal tools against cancer applications [86].
85. Angel J., Chaperot L., Molens J.-P., Mezin P., Amacker M., Zurbriggen R., Grichine A., Plumas J. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine. 2007;25(19):3913–3921. [PubMed] [Google Scholar]
86. Saga K., Kaneda Y. Virosome presents multimodel cancer therapy without viral replication. Biomed. Res. Int. 2013;(2013):764706. [PMC free article] [PubMed] [Google Scholar]
Recently, Great efforts were made to fabricate a virosome-based vaccine platform against a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. (1st paragraph)
Conclusion:
To date, many virosome products are approved by administration authorities in different countries and commercialized. ***Not a single one by Mymetics***
Transvac 2 is a new virosomal vaccine designed against sarscov2 viruses that are in phase ?? clinical trials.
Market Data 
Markets 
AI
